Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
76.72
+0.82 (+1.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
33
34
Next >
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
September 08, 2023
Gilead shares are on the rise amid an unexpected boon for its HIV treatment business.
Via
Investor's Business Daily
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
September 08, 2023
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
September 08, 2023
Via
Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
September 08, 2023
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean...
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
September 07, 2023
Via
Benzinga
Where Gilead Sciences Stands With Analysts
September 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
September 05, 2023
Via
Benzinga
3 No-Brainer Dividend Stocks to Buy in September
September 02, 2023
Income investors should really like these biopharma stocks with juicy dividends.
Via
The Motley Fool
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
August 11, 2023
Via
Benzinga
How Is The Market Feeling About Gilead Sciences?
August 10, 2023
Via
Benzinga
2 High-Yield Dividend Stocks to Buy on the Dip
August 08, 2023
The market may have been a bit too harsh on these stocks.
Via
The Motley Fool
Nearing Retirement? These Stocks Will Pay You For Life
August 29, 2023
These companies are passive income machines.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
August 28, 2023
Via
Benzinga
GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment
August 24, 2023
Gilead Sciences (GILD) stock is on the move Thursday following additional FDA approval for its Veklury Covid-19 treatment.
Via
InvestorPlace
Exposures
COVID-19
Product Safety
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...
Via
Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
August 23, 2023
Roche provided an update from its study in lung cancer using an anti-TIGIT drug.
Via
Investor's Business Daily
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
August 04, 2023
GILD earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?
August 03, 2023
Gilead missed earnings expectations Thursday, though reported strong sales growth for cancer drugs.
Via
Investor's Business Daily
San Francisco Business Times Names Landis Communications Inc. (Landis) the Top 2022 Bay Area Corporate Philanthropist as a Percentage Of Profits
August 22, 2023
--News Direct--
Via
News Direct
Topics
LGBTQ
Exposures
Diversity
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
August 21, 2023
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years.
Via
Talk Markets
FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients
August 21, 2023
FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S.
Via
Benzinga
Exposures
Product Safety
5 Safe Stocks Under $40 to Buy Immediately
August 21, 2023
Investors are turning away from risky bets and putting their money in safe stocks this week. Here are four names under $40 to buy now.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
August 17, 2023
Via
Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
August 17, 2023
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
Via
Benzinga
The 3 Best Biotech Stocks to Buy in August
August 09, 2023
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news.
Via
InvestorPlace
Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation
August 04, 2023
Gilead Sciences Inc's (NASDAQ: GILD) Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by...
Via
Benzinga
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
August 03, 2023
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost.
Via
Benzinga
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review
August 04, 2023
Amazon, ELF and CAT were earnings winners, but there were big losers too.
Via
Investor's Business Daily
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
August 01, 2023
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now.
Via
InvestorPlace
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.